Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Antiallergic agent, stabilizer of membranes of mast cells. It inhibits the release of histamine, leukotrienes and other biologically active substances from mast cells. It is believed that the delay in the release of mediators occurs as a result of an indirect blockade of the penetration of calcium ions into the cells. It has been established that cromoglycic acid inhibits the migration of neutrophils, eosinophils, monocytes.
Prevents asthmatic reactions of immediate and delayed type after inhaling allergens and non-antigenic stimuli.
PHARMACOKINETICS
The degree of absorption of the active substance depends on the mode of administration.
Binding to plasma proteins is 65%. It is not metabolized. T 1/2 is about 1.5 hours. It is excreted unchanged in urine and bile in approximately equal amounts.
INDICATIONS
Bronchial asthma (atopic form, asthmatic triad, asthma of physical effort), chronic bronchitis with bronchoobstructive syndrome. Prevention and treatment of allergic conjunctivitis and keratoconjunctivitis. Prevention of seasonal and / or all-year-round rhinitis of allergic origin. Food allergy (with proven antigen). In the combination therapy with NNC, proctitis or proctocolitis.
DOSING MODE
Individual. For inhalations - 1-10 mg (depending on the dosage form used) 4 times / day.
Inside adults - 200 mg 4 times / day, children aged 2 to 14 years - 100 mg 4 times / day.
When used in ophthalmology and ENT-practice, the dose is set depending on the indications and the dosage form used.
Rectally applied in the form of microclysters.
SIDE EFFECT
With inhalation administration: irritation of the upper respiratory tract, cough, short-term bronchospasm; in some cases - pronounced bronchospasm with a decrease in the function of external respiration.
With intranasal administration: at the beginning of treatment, irritation of the mucous membrane of the nasal cavity is possible; in isolated cases - nasal bleeding, allergic reactions.
With topical application in ophthalmology: possible temporary violation of the clarity of visual perception, a feeling of heat in the eye.
Allergic reactions: in single cases - skin rash, joint pain.
Other: in isolated cases - nausea.
CONTRAINDICATIONS
I trimester of pregnancy, children under 5 years (for inhalation application in the form of an aerosol), up to 2 years (in the form of capsules with powder for inhalation and solution for inhalation use); increased sensitivity to cromoglycic acid.
PREGNANCY AND LACTATION
Cromoglycic acid is contraindicated in the first trimester of pregnancy.
Use in the II and III trimesters of pregnancy is possible only if the perceived benefit to the mother exceeds the potential risk to the fetus.
In small amounts excreted in breast milk. Application in the lactation period is possible only if the intended benefit to the mother exceeds the potential risk for the baby.
APPLICATION FOR FUNCTIONS OF THE LIVER
With caution apply with concomitant diseases of the kidneys.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
With caution apply with concomitant liver diseases.
APPLICATION FOR CHILDREN
Children under the age of 2 years are not given a dose of cromoglycic acid for inhalation in the form of powder and solution.
Children under the age of 5 years have not been given a dose of cromoglycic acid for inhalation in the form of aerosol and for intranasal use.
SPECIAL INSTRUCTIONS
Do not apply for arresting an acute attack of bronchial asthma.
With caution apply with concomitant diseases of the liver and kidneys.
In exceptional cases, when inhaled cromoglycic acid develops bronchospasm with a decrease in the function of external respiration, repeated use is not recommended.
In the treatment of NNC, proctitis or proctocolitis, cromoglycic acid is the drug of choice in patients with hypersensitivity to sulfasalazine.
In inhalation solution of cromoglycic acid, do not simultaneously use bromhexine and ambroxol.
With food allergies should be used in combination with a diet that limits the intake of antigen.
Children under the age of 2 years are not given a dose of cromoglycic acid for inhalation in the form of powder and solution.
Children under the age of 5 years have not been given a dose of cromoglycic acid for inhalation in the form of aerosol and for intranasal use.
Impact on the ability to drive vehicles and manage mechanisms
For some time after instillation in the eye should refrain from performing work that requires increased attention.
DRUG INTERACTION
When using cromoglycic acid with oral and inhalation forms of beta-adrenostimulants, oral and inhalation forms of GCS, theophylline and other methylxanthine derivatives, antihistamines, a potentiation effect is possible. The combined use of cromoglycic acid and GCS can reduce the dose of the latter, and in some cases - completely cancel. During the dose reduction, the patient should be under close medical supervision, the rate of dose reduction should not exceed 10% per week.
In an inhalation solution, it is pharmaceutically incompatible with bromhexine or ambroxol. Bronchodilators should be taken (inhaled) before inhalation of cromoglycic acid.
With topical application in ophthalmic practice, cromoglycic acid reduces the need for ophthalmic drugs containing GCS.
